Loading stock data…
4543.T
TSE¥2,025-31.00 (-1.51%)
Market ClosedLast close Apr 27
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Terumo Corporation in the Healthcare sector is trading at ¥2,025. The stock is currently near its 52-week low of ¥1,900, remaining 13.0% below its 200-day moving average. Technical signals show oversold RSI of 23 and bearish MACD signal, explaining why 4543.T maintains its current current market pressure. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 23) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price¥2,025
Potential Downside
15.4%
Whystock Fair Value¥1,713
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Buy
Mean target¥2,872+41.8%
Range¥2,100 – ¥3,700
Fundamentals
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. It operates through three segments: Cardiac and Vascular Company, Medical Care Solutions C...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥3.05T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.34
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Strong income play. Yield provides a meaningful total return floor.
142.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.74%
Volume
Today's trading volume
5.08M
Recent News
Did Terumo’s (TSE:4543) New Tata Elxsi Partnership and Bond Shelf Just Reframe Its Investment Narrative?
In March 2026, Terumo Corporation filed a shelf registration for up to ¥200 billion in bonds and, a few days earlier, Tata Elxsi announced the opening of the Terumo–Tata Elxsi Offshore Development Center to support Terumo’s cardiac and vascular solutions worldwide. The creation of this dedicated Offshore Development Center highlights Terumo’s push to combine advanced engineering, AI-enabled software, and regional customization to enhance its cardiac and vascular device portfolio and...
Terumo Record Q3 Highlights OrganOx Integration And Margin Story For Investors
Terumo (TSE:4543) reported record-high revenue and profit for its third quarter. North American demand and contributions from the recently acquired OrganOx business supported the result. The quarter also featured improved profit margins alongside the new revenue high. Terumo, a major medical technology group, is seeing its latest quarter shaped by hospital and procedure volumes, reimbursement trends, and ongoing demand for devices that support cardiovascular and surgical care. The record Q3...
Terumo Corp (TRUMF) Q3 2026 Earnings Call Highlights: Record Revenue and Strategic Acquisitions ...
Despite challenges from tariffs and foreign exchange, Terumo Corp (TRUMF) achieves record-high revenue and operating profit, driven by strong North American demand and strategic acquisitions.
Okami raises $45M to commercialize vascular embolization devices
The company named former Inari Medical CEO Drew Hykes as its next leader in conjunction with the financing round.
Terumo (TSE:4543): Evaluating Value After Prolonged Share Price Decline
Terumo (TSE:4543) has recently caught the attention of investors following a sustained share price decline over the past month, with the stock down nearly 5% and extending to a 14% drop over the past 3 months. This pullback provides an interesting vantage point for those tracking trends in the healthcare sector. See our latest analysis for Terumo. Terumo’s recent pullback continues a broader downward trend, with the share price returning -20.87% year-to-date and the 1-year total shareholder...